Ashwagandha takes the lead to be the mother nature’s COVID-19 warrior: Study
They discovered that Withanone (Wi-N), a natural compound derived from Ashwagandha (Withania somnifera) and Caffeic Acid Phenethyl Ester (CAPE), an active ingredient of New Zealand propolis, have the potential to interact with and block the activity of Mpro. The team described that they have also searched for the capability to these bioactives to modulate the protein on the surface of human cells, to which the SARS-CoV-2 binds and allows its entry into our cell - the transmembrane protease serine 2 (TMPRSS2), and selected Withanone. The study is currently under review and expected to be published in a near future.
The team said that their findings may not only connect to save time and cost required for screening for anti-COVID-19 drugs, but may also offer some preventive and therapeutic value for the management of fatal COVID-19 pandemic, and hence warrant prioritized validation in the laboratory and clinical tests. They added that the drug development may take a while and in the current scenario, these natural resources (Ashwagandha and Propolis) may offer some preventive or even therapeutic value. However, although they are easily available and affordable, one has to be cautious about the content of bioactive ingredients. CAPE, while is a major component of propolis, its amount and stability are critical factors that could be managed by generating its complex with cyclodextrins. This has been earlier described by the DAILAB team. Withanone, on the other hand, varies with geography/parts/size of the Ashwagandha plant. So, in order to acquire or appreciate particular effects, we must use the right and quality-controlled resource/extracts.
No comments:
Post a Comment